[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-solid-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-solid-tumors":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,47,83,110,131,183,212,250,274,313,380,413,446,478,499,520,539,563,589,619,642,667,685,709,745],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100648964","slr-108-pet-imaging-in-subjects-with-metastatic-solid-tumors-100648964",false,"NCT07728942","SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors","A Phase 1 Study of the Antibody-Radionuclide Conjugate SLR-108 for Positron Emission Tomography Imaging in Subjects With Metastatic Solid Tumors","Inclusion Criteria\n\n* Men or women (as appropriate for cancer type) of age ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records.\n* Based on the most recent tumor assessment, presence of metastatic disease that has progressed during or following previous treatment.\n* Presence of radiographically measurable disease (defined as the presence of ≥1 non-osseous tumor lesion that measures ≥10 mm in longest dimension \\[≥15 mm in shortest dimension for lymph nodes\\] and is outside of any prior radiation field).\n* Prior receipt of commercially available therapies that are indicated for the subject's cancer and have a demonstrated survival benefit for that indication.\n* Availability of tumor tissue from fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival sample from a previous biopsy.\n* Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before study drug administration.\n* Adequate hematological profile.\n* Adequate coagulation profile.\n* Adequate hepatic profile.\n* Adequate renal function.\n* Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infection.\n* For female subjects of childbearing potential, a negative serum pregnancy test.\n* For female subjects of childbearing potential, willingness to use a protocol recommended method of contraception from the start of the screening period until ≥6 months after study drug administration.\n* For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol recommended method of contraception from the start and until ≥6 months after study drug administration and to refrain from sperm donation from the start and until ≥12 months after study drug administration.\n* Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including any required tumor biopsy\u002Faspirations and all radiographic studies), and study restrictions.\n* Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the study drug, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n* Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n* Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n* Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of study drug administration.\n* Significant cardiovascular event or comorbidity.\n* Significant screening ECG abnormalities.\n* Pregnancy or breastfeeding.\n* Any medical condition preventing PET\u002FCT scanning, and\u002For inability to tolerate up to 60 minutes of PET\u002FCT scanning per imaging session, and\u002For ineligibility for PET\u002FCT scanning due to the weight limits of the scanner.\n* Major surgery within 4 weeks before study drug administration.\n* Use of a drug known to prolong the QT interval within 7 days prior to study drug administration.\n* Anticipated use of a strong inhibitor or inducer of cytochrome CYP3A4 or CYP1A2.\n* Concurrent participation in another therapeutic or imaging clinical trial.\n* Any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a subject's ability to provide informed consent, adversely affect the subject's ability to cooperate and participate in the study, or compromise the interpretation of study results.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.",[27],"Metastatic Solid Tumors",[29,30,31,32,33],"metastatic solid tumors","metastatic cancer","solid tumor","positron-emission tomography","PET","RECRUITING","2026-08-06",{"date":37,"type":38},"2026-08-10","ACTUAL",{"date":40,"type":38},"2026-08-04",{"date":42,"type":21},"2028-02",{"name":44,"class":45},"Solve Therapeutics","INDUSTRY",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100650238","phase-1-a-study-of-iov-5001-in-adults-with-advanced-solid-tumors-100650238","NCT07743723","A Study of IOV-5001 in Adults With Advanced Solid Tumors","A Phase 1\u002F2, Multicenter, Multi-cohort, Open-label Study of an Autologous Tumor-infiltrating Lymphocytes (TIL) Regimen With IOV-5001 in Participants With Previously Treated Advanced Solid Tumors","Inclusion Criteria:\n\n1. Participant must be ≥ 18 years of age at the time of signing the informed consent.\n2. Diagnosis:\n\n   NSCLC: Participant has a histologically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC (squamous, nonsquamous, adenocarcinoma, large cell, or mixed histologies) without epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1) genomic alterations.\n\n   TNBC: Participant has a histologically or pathologically confirmed diagnosis of unresectable or Stage IV breast cancer.\n\n   CRC: Participant has a histologically or pathologically confirmed diagnosis of Stage IV CRC.\n\n   HNSCC: Participant has a histologically or pathologically confirmed diagnosis of Stage III or IV HNSCC not amenable to curative intent treatment.\n3. Radiographic disease progression: Participant has radiographic disease progression after the most recent line of therapy.\n4. Disease-specific criterion:\n\n   NSCLC: Radiographic disease progression occurred:\n   * After having received platinum-based chemotherapy and an immune checkpoint inhibitor, either administered concurrently or sequentially for Stage IV disease.\n   * Within 6 months of completion of the platinum component of platinum-based chemotherapy in the adjuvant or neoadjuvant setting and having progressed after receiving an immune checkpoint inhibitor in the neoadjuvant, adjuvant, or metastatic setting.\n\n   TNBC: Participant has received up to 3 prior lines of therapy. These must include at least one prior line of cytotoxic chemotherapy for unresectable or Stage IV breast cancer, regardless of ER, PR, or HER2 status at the time it was given.\n\n   CRC: Participant has received up to 3 prior lines of therapy. These must include a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF therapy, an anti-EGFR therapy (for RAS\u002Frapidly accelerated fibrosarcoma \\[RAF\\] wild-type disease if the tumor originated in the left side of the colon), and an immune checkpoint inhibitor (for microsatellite instability high \\[MSI-H\\] or deficient mismatch repair \\[dMMR\\] disease.\n\n   HNSCC: Participant has received up to 3 prior lines of therapy. These must include an immune inhibitor and platinum-based chemotherapy unless platinum ineligible due to pre-existing hearing loss, Grade \\>= 2 tinnitus, Grade \\>= 2 peripheral neuropathy, or allergy to platinum.\n5. Disease-specific criterion:\n\n   NSCLC: Participant has received up to 3 lines of prior therapy. These must include an appropriate health authority-approved targeted therapy for participants who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations) if eligible and available.\n\n   TNBC: Participant has progressed on or is ineligible for other standard of care therapies including, but not limited to: sacituzumab govitecan, poly(ADP-ribose) polymerase (PARP) inhibitors (if breast cancer gene \\[BRCA\\]1 or BRCA2 mutated), trastuzumab deruxtecan (if HER2low), and pembrolizumab (for PD-L1 combined positive score \\[CPS\\] \\>= 10).\n\n   CRC: Microsatellite instability and\u002For mismatch repair mutational status must have been previously determined based on archival tumor biopsies.\n\n   HNSCC: Participant has documented PD-L1 status.\n6. The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of \\> 6 months.\n7. Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for IOV-5001 generation.\n\nExclusion Criteria:\n\n1. Participants with symptomatic untreated brain metastases. Participants with brain metastases may be enrolled with considerations and discussion with medical monitor.\n2. Participant has an active medical illness(es) that, in the opinion of the investigator would pose increased risks for study participation. Participant has evidence of any active viral, bacterial, or fungal infection requiring ongoing systemic treatment or identified during screening.\n3. Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease \\[SCID\\] or AIDS).\n4. Participant has a history of hypersensitivity to any component of the study intervention.\n5. Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated \\> 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence including, but not limited to: in situ carcinoma of the cervix, early stage skin cancer, including non-melanoma skin cancer, ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) of the breast, prostate cancer with Gleason score ≤ 6, or superficial bladder cancer).\n6. Participant has a history of allogeneic organ transplant or any form of cell therapy involving prior conditioning chemotherapy within the past 20 years.\n7. Participant requires systemic steroid therapy \\> 10 mg\u002Fday of prednisone or another steroid equivalent dose. Participants receiving steroids as replacement therapy for adrenocortical insufficiency at ≤ 10 mg\u002Fday of prednisone or another steroid equivalent dose may be eligible.\n8. Participant received or will receive a live or attenuated vaccination within 28 days prior to the start of the NMA-LD preparative regimen.\n9. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.","70 Years",{"count":56,"type":21},106,[24,58],"PHASE2","A Phase 1\u002F2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors",[61,62,63,64,65,27,66],"Advanced Solid Tumors","Non-Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Unresectable Solid Tumor",[68,69,61,63,27,70,71,72,73],"TIL","Tumor Infiltrating Lymphocytes","Unresectable Solid Tumors","Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","NOT_YET_RECRUITING","2026-08-03",{"date":35,"type":38},{"date":78,"type":21},"2026-08",{"date":80,"type":21},"2044-03",{"name":82,"class":45},"Iovance Biotherapeutics, Inc.",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100607819","phase-1-beacon-1-study-of-avzo-103-as-a-single-agent-and-in-combination-therapy-in-patients-with-locally-advanced-or-metastatic-urothelial-cancer-or-other-solid-tumors-avzo-103-1001-100607819","NCT07193511","BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","A Phase 1\u002F2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4\u002FTrop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","Key Inclusion Criteria:\n\n* Patient must be an adult, 18 years of age and older with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of \\> 3 months.\n* Patients with histologically or cytologically confirmed locally advanced\u002Fmetastatic malignancies for tumor types of preferred indications:\n\n  o Locally advanced or metastatic urothelial cancer and other solid tumors (as specified in the protocol).\n* Measurable disease as assessed by Investigator using RECIST v1.1.\n* Agree to provide molecular test report results to confirm eligibility and archival tumor samples and\u002For fresh biopsy, as applicable.\n* Other protocol-defined Inclusion criteria apply.\n\nKey Exclusion Criteria:\n\n* Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated.\n* Prior Stevens-Johnson syndrome\u002Ftoxic epidermal necrolysis.\n* History of drug-induced interstitial lung disease (ILD).\n* History of any serious cardiovascular condition.\n* Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose.\n* History of allogenic stem cell or solid organ transplant.\n* Other protocol-defined Exclusion criteria apply.",{"count":91,"type":21},355,[24,58],"This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.",[95,96,27,97],"Solid Tumor Cancer","Locally Advanced","Urothelial Cancer",[99,100,96,97],"Solid Tumors","Metastatic",{"date":102,"type":38},"2026-08-05",{"date":104,"type":38},"2025-10-02",{"date":106,"type":21},"2030-09",{"name":108,"class":45},"Avenzo Therapeutics, Inc.",13,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":46},"100650633","phase-1-phase-i-study-of-sm2275-injection-in-patients-with-advanced-solid-tumors-100650633","NCT07750132","Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors","A First-in-Human, Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of SM2275 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older.\n* Able to understand the study requirements and voluntarily provide written informed consent before any study-specific procedures.\n* Histologically or cytologically confirmed advanced or metastatic EGFR-positive and PD-L1-positive solid tumor that has progressed following standard therapy, is intolerant to standard therapy, or for which no effective standard therapy is available, including but not limited to head and neck squamous cell carcinoma, non-small cell lung cancer, unresectable advanced colorectal cancer, and renal clear cell carcinoma.\n* Able to provide archived tumor tissue or other tumor samples as required by the protocol during the screening period.\n* At least one measurable lesion according to RECIST Version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy of at least 12 weeks.\n* Adequate hematologic, hepatic, renal, cardiac, and other organ function as defined in the protocol.\n* Left ventricular ejection fraction (LVEF) greater than 50% as determined by echocardiography (ECHO) or multigated acquisition (MUGA) scan.\n* Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of study treatment.\n* Male participants and female participants of childbearing potential must agree to use highly effective contraception during the study and for at least 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Insufficient washout period from prior anticancer therapy before the first dose of study treatment.\n* Prior anticancer immunotherapy permanently discontinued due to immune-related toxicity, history of Grade 3 or higher immune-related adverse events (irAEs), or history of Grade 2 or higher immune-related myocarditis considered by the investigator to make the participant unsuitable for study participation.\n* History of severe infusion-related reactions associated with prior EGFR-targeted therapy.\n* Receipt of antitumor vaccines or cellular immunotherapy within 3 months before the first dose of study treatment.\n* Presence of another active malignancy requiring treatment.\n* Adverse events from prior anticancer therapy that have not recovered to Grade 1 or baseline, except for alopecia, skin pigmentation of any grade, or Grade 2 or lower peripheral sensory neuropathy.\n* Active autoimmune disease requiring systemic immunosuppressive therapy.\n* Major surgery, open biopsy, or significant traumatic injury within 4 weeks before the first dose; planned major surgery during the study; or incomplete recovery from prior surgery.\n* Active central nervous system (CNS) tumors.\n* Symptomatic heart failure (New York Heart Association Class II or higher).\n* Uncontrolled hypertension (systolic blood pressure greater than 150 mmHg or diastolic blood pressure greater than 100 mmHg despite optimal medical therapy).\n* Fridericia-corrected QT interval (QTcF) greater than 470 milliseconds based on the average of triplicate screening electrocardiograms.\n* Acute coronary syndrome, acute myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery within 6 months before the first dose.\n* Cardiomyopathy of any etiology or clinically significant valvular heart disease.\n* Clinically significant arrhythmias requiring medical treatment (well-controlled atrial fibrillation is permitted).\n* Transient ischemic attack (TIA) or stroke within 6 months before screening.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once per month or ongoing clinical intervention.\n* Active infection requiring systemic antibacterial or antiviral therapy within 14 days before the first dose. Participants receiving stable antiviral therapy for hepatocellular carcinoma or controlled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are permitted.\n* Active or uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Participants with controlled HBV or HCV receiving stable antiviral therapy may be eligible.\n* Known human immunodeficiency virus (HIV) infection.\n* Receipt of systemic immunosuppressive medication within 14 days before the first dose, unless permitted by the protocol.\n* History of interstitial lung disease (ILD), pneumonitis, suspected ILD or pneumonitis that cannot be excluded by screening imaging, or severe chronic obstructive pulmonary disease (COPD).\n* History of severe hypersensitivity to monoclonal antibodies or history of anaphylaxis within 6 months before screening.\n* History of allogeneic organ transplantation or graft-versus-host disease (GvHD).\n* Receipt of a live vaccine within 4 weeks before the first dose.\n* Known substance abuse or psychiatric disorder that, in the opinion of the investigator, would interfere with study participation or protocol compliance.\n* Pregnant or breastfeeding women, or participants planning to conceive or father a child during the study and for at least 6 months after the last dose of study treatment.\n* Any medical condition, laboratory abnormality, or other clinical circumstance that, in the opinion of the investigator, would make the participant unsuitable for study participation or could interfere with the interpretation of study results.",{"count":118,"type":21},72,[24],"This is a first-in-human, multicenter, open-label Phase Ia\u002FIb study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of SM2275 in patients with advanced or metastatic solid tumors who have progressed after standard therapy or for whom no standard treatment is available.\n\nPhase Ia includes dose escalation to evaluate safety, identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) and\u002For recommended Phase II dose (RP2D). Phase Ib will further evaluate safety, PK, PD, and preliminary antitumor activity in expansion cohorts.",[61,27],[123],"SM2275 EGFR PD-L1 CD28 VHH Multispecific Antibody Immunotherapy Solid Tumor First-in-Human","2026-08-01",{"date":35,"type":38},{"date":124,"type":21},{"date":128,"type":21},"2029-02-02",{"name":130,"class":45},"Beijing StarMab Biomed Technology Ltd",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":157,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100646600","a-multicenter-randomized-open-label-trial-evaluating-ctdna-guided-interruption-versus-standard-of-care-immune-checkpoint-inhibitor-ici-therapy-in-patients-with-advanced--metastatic-solid-tumors-100646600","NCT07689812","A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced \u002F Metastatic Solid Tumors.","A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced\u002FMetastatic Solid Tumors","SIGNAL-IO 301","Inclusion Criteria:\n\nGeneral inclusion criteria includes the following selection criteria to be eligible for inclusion in any aspect of the study. Eligibility will be assessed by the investigator:\n\n1. Signed Informed consent\n2. Age ≥ 18 years\n3. ECOG 0-2.\n4. Histologically confirmed advanced\u002Fmetastatic solid tumors including:\n\n   1. Melanoma: Unresectable recurrent, advanced, or metastatic\n   2. NSCLC: Advanced or metastatic\n   3. MSI-High\u002FdMMR CRC: Metastatic\n   4. RCC: Unresectable recurrent, advanced, or metastatic\n   5. Other: Metastatic solid tumors\n5. Received first line ICI monotherapy or dual-ICI therapy (e.g., PD-1\u002FCTLA-4 combination therapy) for a minimum of 12 months (maximum of 15 months) for NSCLC, RCC \\& other metastatic solid tumors, or for a minimum of 6 months (maximum of 9 months) for melanoma and MSI-High \u002FdMMR CRC. Exceptions permitted:\n\n   * For patients with NSCLC: First line platinum-based chemo-ICI regimens if on maintenance ICI +\u002F- pemetrexed.\n   * For patients with melanoma: nivolumab\u002Frelatlimab is permissible.\n6. Radiographic CR\u002FPR: Participants must have CR or PR at the last assessment performed within 6 weeks before randomization according to RECIST v1.1 using a diagnostic CT and\u002For MRI. Radiographic assessment must be confirmed by the BICR prior to randomization.\n7. Known ctDNA-negative with a tissue-informed assay\n\n   * ≥ 2 consecutive ctDNA-negative results at least 6 weeks apart; last test within 1 month of enrollment.\n   * Note: A confirmatory Signatera Genome negative test must be completed at enrollment if previous ctDNA testing performed for clinical care was done with a test other than Signatera Genome.\n8. Adequate organ function:\n\n   1. Hematology: ANC ≥1500\u002FμL; Platelets ≥100000\u002FμL;Hemoglobin ≥9.0g\u002FdL;\n   2. Renal: Serum Cr ≤1.5×ULN or calculated CrCl ≥60 mL\u002Fmin (using Cock-Gault formula);\n   3. Hepatic: Total bilirubin ≤1.5 ×ULN or, for participants with total bilirubin levels \\>1.5×ULN, direct bilirubin within normal limits; AST (SGOT) and ALT (SGPT) ≤2.5×ULN;\n   4. Coagulation: INR or PT, activated partial thromboplastin time (APTT) ≤1.5×ULN Note: Laboratory assessments performed as part of standard of care evaluations during immunotherapy treatment administration may be used to satisfy these eligibility criteria, provided they are obtained within 28 days of enrollment.\n9. Recovery to baseline or ≤ Grade 1 common terminology criteria for adverse events (CTCAE) v6 from AE(s) related to any prior treatments unless AE(s) are deemed clinically non-significant (e.g., Grade 2 alopecia) by the Investigator and\u002For stable on supportive therapy.\n10. No prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since completion of definitive therapy\n11. Participants must be willing and able to comply with study visits, treatment plans, laboratory tests, and other study procedures\n12. Women of child-bearing potential (WOCBP) and male participants partnering with WOCBP must agree to use highly effective contraception during the treatment phase and at least 180 days post last dose\n13. Patients must be willing to discontinue clinically-directed ctDNA testing for treatment response monitoring during the period of clinical trial testing as dictated by the protocol.\n\nExclusion Criteria\n\nPatients are not eligible for the study if they meet any of the following criteria, as assessed by the investigator:\n\n1. Available alternate treatment options with curative intent, e.g. surgery and \u002F or RT and \u002F or Chemotherapy.\n2. Symptomatic or progressing CNS metastases; or presence of leptomeningeal disease.\n3. Patient has active autoimmune disease that required systemic treatment in the past 2 years, is immunocompromised in the opinion of the Investigator, or is receiving systemic immunosuppressive treatment. (Note: Participants with splenectomy are allowed.) Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment.\n4. Patient is receiving systemic steroid therapy ≤3 days prior to enrollment or receiving any other form of immunosuppressive medication with the exception of daily steroid replacement therapy. Note: Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.\n5. Had allogeneic tissue\u002Fsolid organ transplantation.\n6. Interstitial lung disease or history of pneumonitis that has required oral or IV steroids. Note: Patients with lymphangitic carcinomatosis secondary to NSCLC can be considered as eligible.\n7. Has received or will receive a live vaccine within 30 days prior to enrollment (seasonal flu vaccines that do not contain live vaccine are permitted).\n8. Active infection requiring intravenous systemic therapy.\n9. Known history of human immunodeficiency virus (HIV).\n10. Known active Hepatitis B or C.\n11. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study.\n12. Currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of enrollment.\n13. Use of any commercial ctDNA or liquid biopsy monitoring outside of the study protocol during the treatment monitoring phase within the protocol.",{"count":140,"type":21},920,[142],"NA","This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI therapy in patients with histologically confirmed advanced\u002Fmetastatic non-small cell lung cancer (NSCLC), melanoma, microsatellite instability-high (MSI-High)\u002FDeficient Mismatch Repair (dMMR) colorectal cancer (CRC), renal cell carcinoma (RCC) and other solid tumors. This study will be conducted in up to 100 sites.",[145,146,147,148,149,150,151,152,153,154,155,99,27,61,156],"NSCLC (Advanced Non-small Cell Lung Cancer)","NSCLC (Non-small Cell Lung Cancer)","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC","Melanoma (Skin Cancer)","Melanoma (Skin) Stage IV","CRC","MSI High Colorectal Cancer","DMMR Colorectal Cancer","RCC, Renal Cell Cancer","RCC","Advanced Solid Tumors Cancer",[158,159,160,161,162,148,163,164,165,64,151,166,155,167,168,169,170,171,172,173,174],"ctDNA","Circulating tumor DNA","Immune checkpoint inhibitor","ICI","Non-small cell lung cancer","Melanoma","Microsatellite Instability-High\u002Fdeficient Mismatch Repair","MSI-High\u002FdMMR","Renal cell carcinoma","Metastatic solid tumors","Signatera","Molecular residual disease","MRD","Biomarker-guided therapy","Adjuvant therapy","Tumor-informed assay","Advanced solid tumor","2026-07-31",{"date":40,"type":38},{"date":178,"type":21},"2026-12",{"date":180,"type":21},"2034-03",{"name":182,"class":45},"Natera, Inc.",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100623492","phase-1-study-of-rason-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors-100623492","NCT07397338","Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","A Phase 1\u002F2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically confirmed, locally advanced or metastatic solid tumor malignancy with documented RAS mutation in KRAS, HRAS, or NRAS.\n* Received and progressed or been intolerant to prior standard therapy (Part 1 Dose Exploration).\n* Non-squamous NSCLC without a treatable driver mutation in other oncogenes that has not received prior systemic treatment (Arms A \\& B for Part 2 Dose Expansion).\n* Solid tumor or CRC previously treated with no more than 2 prior lines of therapy for advanced disease and progressed or been intolerant to prior standard therapies (Arm C for Part 2 Dose Expansion).\n* Measurable disease per RECIST v1.1\n* Adequate organ function (bone marrow, liver, kidney, coagulation, endocrine).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Head and neck squamous cell carcinoma.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 4 weeks prior to receiving study drug(s).\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.\n* Other inclusion\u002Fexclusion criteria may apply.",{"count":191,"type":21},370,[24,58],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.",[61,27,195,148,72,151],"Non-small Cell Lung Cancer (NSCLC)",[61,27,197,148,64,151,198,199,200,201,202],"Non-small Cell Lung Cancer","RAS","NRAS","KRAS","HRAS","RAS Mutation","2026-07-30",{"date":75,"type":38},{"date":206,"type":38},"2026-01-30",{"date":208,"type":21},"2029-05",{"name":210,"class":45},"Revolution Medicines, Inc.",9,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100591693","phase-1-a-study-of-eras-0015-in-patients-with-advanced-or-metastatic-solid-tumors-100591693","NCT06983743","A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors","A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors","AURORAS-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts.\n* There is no available standard systemic therapy available for the patient's tumor histology and\u002For molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy. Does not apply to newly diagnosed Pancreatic Ductal Carcinoma (PDAC) cohort.\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n\nExclusion Criteria:\n\n* Previous treatment with a RAS inhibitor\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-0015\n* Received prior palliative radiation within 14 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) tumors\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial","99 Years",{"count":222,"type":21},600,[24],"The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.",[27],[227,228,229,230,231,232,233,234,235,236,237,64,238,239,240],"Solid Tumor","Advanced Solid Tumor","solid malignancies","Targeted therapy","Molecular alterations","pembrolizumab","KEYTRUDA ®","panitumumab","Vectibix","Metastatic Solid Tumor","Neoplasms","Non-small cell lung cancer (NSCLC)","Newly diagnosed Pancreatic Ductal Adenocarcinoma","NSCLC patients previously treated with a KRAS G12c inhibitor","2026-07-29",{"date":175,"type":38},{"date":244,"type":38},"2025-06-05",{"date":246,"type":21},"2028-12-01",{"name":248,"class":45},"Erasca, Inc.",8,{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100503520","phase-1-a-study-to-evaluate-the-safety-of-inca33890-in-participants-with-advanced-or-metastatic-solid-tumors-100503520","NCT05836324","A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically or cytologically confirmed advanced or metastatic malignancies as defined in the protocol.\n* Part 1: Participants must have experienced disease progression after treatment with, be intolerant to, or be ineligible for, or refused available therapies, including anti-PD-(L)1 or anti-CTLA4 therapy if applicable, that are known to confer clinical benefit. Part 2: depending on cohort, participants may have received or not prior treatment for the malignancy under study.\n* ECOG performance status score of 0 or 1.\n* Willingness to undergo pre- and on-treatment tumor biopsy (core or excisional). Biopsies are mandatory depending on the cohorts.\n* Presence of measurable disease according to RECIST v1.1.\n\nExclusion Criteria:\n\n* Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years.\n* Not recovered to ≤ Grade 1 or baseline from residual toxicities of prior therapy.\n* Has active autoimmune disease requiring systemic immunosuppression with corticosteroids.\n* Brain or CNS metastases untreated or that have progressed.\n* History of organ transplant, including allogeneic stem cell transplantation.\n* History of clinically significant or uncontrolled cardiac disease.\n* Active HBV, active HCV, or HIV positive.\n* Is on chronic systemic steroids (\\> 10 mg\u002Fday of prednisone or equivalent).\n* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment\n* Participants that have been initiated on or had modifications in anticoagulation therapies within the last 3 months prior to first dose of treatment.\n* Significant concurrent, uncontrolled medical condition, eg:\n\n  * Cardiovascular: Participants with known vasculitis, aneurisms, and other vascular malformations of clinical significance or history of myocarditis.\n  * Gastrointestinal: Any bowel obstruction within 60 days prior to C1D1.\n* Participants with adequate laboratory values within the protocol defined ranges.\n\nOther protocol-defined Inclusion\u002FExclusion Criteria may apply.",{"count":258,"type":21},570,[24],"To evaluate the safety, tolerability, and DLTs and determine the MTD and\u002For RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.",[99,61,27],[99,263],"INCA33890","2026-07-21",{"date":266,"type":38},"2026-07-23",{"date":268,"type":38},"2023-07-24",{"date":270,"type":21},"2029-05-03",{"name":272,"class":45},"Incyte Corporation",39,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":211},"100611245","phase-1-adcx-020-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-cancers-100611245","NCT07238075","ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers","A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a\u002Fb Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Male and female participants ≥ 18 years of age\n* Ph1a: Locally advanced or metastatic solid tumor relapsed or PD following local standard treatments, for which no standard treatment is available\n* Ph1b: Eligible patients should have only received prior lines of systemic therapy according to SoC in the advanced\u002Fmetastatic setting (not counting neoadjuvant\u002Fadjuvant treatment if completed \\>6 months prior to recurrence)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Radiologically measurable disease by RECIST v1.1\n* Mandatory adequate tumor tissue sample available\n* Must have recovered from all clinically relevant toxicities from previous cancer therapies (to at least Grade 1, except for alopecia)\n\nExclusion Criteria:\n\n* Known allergies\u002Fhypersensitivity\u002Fintolerance to or contraindication to exatecan, or any excipient\n* Phase 1b: Prior antibody drug conjugate exposure with a topoisomerase 1 inhibitor payload\n* Uncontrolled or significant cardiac disease including left ventricular ejection fraction (LVEF) \\\u003C50%, myocardial infarction or uncontrolled\u002Funstable angina\n* Has clinically active central nervous system (CNS) metastases\n* Has a history of lung fibrosis or non-infectious interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n* Active corneal disease, or history of corneal disease within 12 months prior to enrollment\n* Other unacceptable abnormalities, medications or procedures as defined by protocol",{"count":282,"type":21},290,[24],"The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate.\n\nThis study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.",[286,287,27],"Advanced Malignancy","Advanced Solid Cancers",[289,290,291,237,292,293,294,295,296,297,298,299,300,301,302,303],"Antibody Drug Conjugate","Antineoplastic Agents","Monoclonal Antibodies","Response Evaluation Criteria in Solid Tumors (RECIST)","Phase 1 clinical trial","Maximum Tolerated Dose","Open-Label Trials","Multicenter Study","Pharmacokinetics","Pharmacodynamics","Drug-Related Side Effects and Adverse Reactions","Dose-Response Relationship, Drug","Adults","Progression-Free Survival \u002F Overall Survival","Overall response rate","2026-06-05",{"date":306,"type":38},"2026-06-08",{"date":308,"type":38},"2026-02-23",{"date":310,"type":21},"2029-11-30",{"name":312,"class":45},"Adcytherix SAS",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":321,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100292920","phase-1-a-study-of-repotrectinib-tpx-0005-in-patients-with-advanced-solid-tumors-harboring-alk-ros1-or-ntrk1-3-rearrangements-100292920","NCT03093116","A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","A Phase 1\u002F2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)","TRIDENT-1","PHASE 1\n\nKey Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.\n2. ECOG PS 0-1.\n3. Age ≥18 (or age ≥ 20 of age as required by local regulation).\n4. Capability to swallow capsules intact (without chewing, crushing, or opening).\n5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.\n6. Prior cytotoxic chemotherapy is allowed.\n7. Prior immunotherapy is allowed.\n8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.\n9. Patients with asymptomatic CNS metastases (treated or untreated) and\u002For asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500\u002Fmm3 (1.5 × 109\u002FL); Platelets (PLTs) ≥100,000\u002Fmm3 (100 × 109\u002FL); Hemoglobin ≥ 9.0 g\u002FdL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or \\> 40 mL\u002Fmin; Total serum bilirubin \\\u003C 1.5 × ULN; Liver transaminases (ASTs\u002FALTs) \\\u003C 2.5 × ULN; \\\u003C 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \\\u003C 2.5 × ULN; \\\u003C 5 × ULN if liver and\u002For bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation\n11. Life expectancy ≥ 3 months.\n\nPHASE 2 Key Inclusion Criteria\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.\n2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:\n\n   1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.\n\n      • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.\n\n      OR\n   2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.\n\n      * Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.\n4. Age ≥12 (or age ≥ 20 as required by local regulation).\n5. Willing and able to provide written institutional review board (IRB)\u002Finstitutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.\n6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.\n7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.\n\n   i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors\n8. Subjects with asymptomatic CNS metastases (treated or untreated) and\u002For asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500\u002Fmm3 (1.5 × 109\u002FL); Platelets (PLTs) ≥100,000\u002Fmm3 (100 × 109\u002FL); Hemoglobin ≥ 9.0 g\u002FdL transfusions are allowed; Serum creatinine or creatinine clearance \\> 40 mL\u002Fmin; Total serum bilirubin \\\u003C 1.5 × ULN; Liver transaminases (ASTs\u002FALTs) \\\u003C 2.5 × ULN; \\\u003C 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); \\\u003C 2.5 × ULN; \\\u003C 5 × ULN if liver and\u002For bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation\n10. Life expectancy ≥ 3 months.\n\nKey Exclusion Criteria PHASE 1 and PHASE 2\n\n1. Concurrent participation in another therapeutic clinical trial.\n2. Symptomatic brain metastases or leptomeningeal involvement.\n3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.\n4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry\n5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary\u002Fperipheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2\n6. Any of the following cardiac criteria:\n\n   Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) \\> 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\> 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.\n7. Known active infections (bacterial, fungal, viral including HIV positivity).\n8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.\n9. Peripheral neuropathy of CTCAE ≥grade 2.\n10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.","12 Years",{"count":323,"type":21},500,[24,58],"Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.\n\nMidazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.\n\nPhase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.",[327,27],"Locally Advanced Solid Tumors",[329,330,331,332,333,334,148,335,336,337,338,339,340,341,342,237,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,99,363,319,364,365,366,367,368,369],"ALK","ROS1","NTRK","Sarcoma","Lung Neoplasms","Carcinoma, NSCL","Non Small Cell Lung","Thyroid Disease","Colonic Neoplasms","Thyroid Neoplasms","Carcinoma, Neuroendocrine","Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Lung Disease","Respiratory Tract Disease","Carcinoma, Bronchogenic","Bronchial Neoplasms","Endocrine System Disease","Colorectol Neoplasms","Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Disease","Colonic Disease","Intestinal Disease","Endocrine Gland Neoplasms","Head and Neck Neoplasms","Neuroendocrine Tumors","Neuroectodermal Tumors","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Adenocarcinoma","Non Small Cell Lung Cancer","Rearrangements","TKI","TKI naive","TKI pretreated","Anti-tumor activity","Repotrectinib","Advanced Solid Malignancies","2026-05-26",{"date":372,"type":38},"2026-05-27",{"date":374,"type":38},"2017-03-07",{"date":376,"type":21},"2028-02-29",{"name":378,"class":45},"Turning Point Therapeutics, Inc.",165,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":393,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":46},"100610198","the-sarah-nanotechnology-system-for-treatment-of-advanced-metastatic-solid-tumors-using-hyperthermia-100610198","NCT07224464","The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.","Open Label Feasibility Dose Escalation Study to Evaluate the Safety of Sarah Nanotechnology System, With Alternating Magnetic Field (AMF) Application in Patients With Advanced Metastatic Solid Tumors.","Inclusion Criteria:\n\n1. Life expectancy of at least 90 days.\n2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have progressed on or after standard therapy and are ineligible for surgical resection or local therapies.\n3. Must have measurable disease according to RECIST 1.1.\n4. Locally advanced or metastatic disease which is not amenable to curative therapy and has progressed on or is intolerant to standard available therapy as deemed by the investigator.\n5. There must be resolution of all systemic treatment-related adverse events. At least 14 days must have elapsed since the last systemic or radiotherapy treatment before screening visit.\n6. Documented progressive disease confirmed by either CT (chest and abdomen), MRI or PET\u002FCT scan since patient's last cancer therapy.\n7. No prior history of brain metastasis confirmed by CT or MRI within 30 days prior to treatment.\n8. Treatment planning CT scan performed within 14 days prior to study treatment.\n9. Age ≥18 years.\n10. Rib cage circumference ≤ 90 cm.\n11. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n12. Patients should have sufficient organ and bone marrow function on screening day and on procedure day as defined below:\n\n    Leukocytes ≥3,000\u002FmcL Absolute neutrophil count ≥1,500\u002FmcL Platelets ≥100,000\u002FmcL Total bilirubin ≤ 2.5 x limit of normal (ULN) AST(SGOT)\u002FALT(SGPT) ≤5 x institutional ULN Creatinine Glomerular filtration rate (GFR) ≥50 ml\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal.\n13. Ability to provide written informed consent document.\n14. Confirmation that patient has no electronic or electronically conductive implants or metals:\n\n    * Via a review of the CT scan\n    * Metal questionnaire filled in by patients\n\nExclusion Criteria:\n\n1. Received chemotherapy, radiotherapy or hormonal therapy within 14 days (before screening).\n2. Received immunotherapy\u002Fbiological therapy or any other investigational agent in the last 21 days (before screening).\n3. Not yet recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1).\n4. Presence of brain metastases or prior history of brain metastases (if no prior history, confirmed by CT or MRI within 30 days prior to treatment).\n5. Known history of allergic reactions attributed to compounds of similar chemical or biological composition (For example: PEG 20,000 Dalton).\n6. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, ischemia, or psychiatric illness) that in the opinion of the investigator would either limit compliance with study requirements or put participant at risk.\n7. Pregnant and\u002For breastfeeding.\n8. Unwilling to be abstinent or on contraception for up to 30 days after the last study treatment.\n9. Presence of electronic or electronically conductive implants or metals in body (verified by screening CT and metal questionnaire).\n10. Rib cage circumference over 90 cm.\n11. Unable to provide written informed consent.\n12. Unable to lay down with hands extended over head.",{"count":388,"type":21},12,[142],"This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Eligible participants have stage 4 metastatic solid tumor(s), that is(are) not responding to conventional treatment or have declined standard treatment options.\n\nThe main question it aims to answer is:\n\n• What is the safety profile of the Sarah Nanotechnology System and which field strength and time of irradiation are safe for people?\n\nStudy participation involves:\n\n* One intravenous injection (through a vein in the arm) of a solution that contains tiny particles (nanoparticles) containing iron oxide. The nanoparticles are delivered to the tumor(s) through blood circulation.\n* About 4 hours after injection of the nanoparticles, participants are placed inside a machine (magnetic field system) where the upper torso will be exposed to low frequency (\\~300 kHz) alternating magnetic field (AMF) radiation. This type of radiation, unlike CT or X- rays, is non-ionizing. Non-ionizing means radiation that lacks the energy to remove electrons from an atom. Examples of devices that produce non-ionizing radiation are MRI machines, cell phones, Wi-Fi, microwave ovens, and sunlight.\n\nThe AMF heats up the iron oxide core in the nanoparticles, due to their magnetic properties, which in turn causes the temperature to increase within the tumor(s). Because cancer cells are more sensitive to heat than normal cells, the heat will damage the cancer cells potentially without harming the surrounding healthy tissues.\n\n* During the treatment participants are covered by a cooling blanket to control body temperature, which will be monitored continuously throughout the procedure.\n* Participants are followed up at 1 week and 1 month, and up to 5 years after the one-time treatment.",[27,392],"Stage 4 Cancer",[394,395,396,397,398,399,400,401,402,403,27],"Advanced metastatic solid tumors","Stage 4 cancer","Stage 4 liver cancer","Stage 4 ovarian cancer","Stage 4 colon cancer","Stage 4 breast cancer","Stage 4 lung cancer","Stage 4 cervical cancer","Stage 4 cholangiocarcinoma","Hyperthermia","2026-05-13",{"date":406,"type":38},"2026-05-15",{"date":408,"type":38},"2025-12-16",{"date":410,"type":21},"2030-12",{"name":412,"class":45},"New Phase Ltd.",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":22,"phases":423,"briefSummary":424,"conditions":425,"keywords":430,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":445},"100595891","phase-1-aventine-1-study-of-avzo-1418-as-a-single-agent-and-in-combination-therapy-in-patients-with-locally-advanced-or-metastatic-solid-tumors-avzo-1418-1001-100595891","NCT07038343","AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","A Phase 1\u002F2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors","Key Inclusion Criteria\n\n* Patient must be an adult, between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 and a life expectancy of \\> 3 months.\n* Patients with histologically or cytologically confirmed locally advanced\u002Fmetastatic malignancies for tumor types of preferred indications:\n\n  o Locally advanced or metastatic epithelial solid tumors (as specified in the protocol).\n* Measurable disease as assessed by Investigator using RECIST v1.1.\n* Agree to provide molecular test report results to confirm eligibility and archival tumor samples and\u002For fresh biopsy, as applicable.\n* Other protocol-defined Inclusion criteria apply.\n\nKey Exclusion Criteria\n\n* Uncontrolled hypertension.\n* Patients with active central nervous system (CNS) metastases are not eligible. Patients with asymptomatic and treated brain metastases may participate if they are radiologically stable for at least 4 weeks prior to the first dose of this study and do not require steroid treatment. Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated.\n* History of drug-induced interstitial lung disease (ILD).\n* History of any serious cardiovascular condition.\n* Infection requiring IV antibiotics, antivirals, or antifungals within 2 weeks prior to first dose.\n* History of a solid organ transplant.\n* Other protocol-defined Exclusion criteria apply.","75 Years",{"count":422,"type":21},480,[24,58],"This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.",[95,96,27,426,427,428,97,429],"Lung Cancers","Epithelial Tumor","Biliary Tract Cancer (BTC)","Nasopharyngeal Cancers",[99,100,96,431,432,433,97,434,435,436,437,438,148],"Lung Cancer","Epithelial Solid Tumors","Biliary Tract Cancer","SCLC","HER3","EGFR","BTC","Small Cell Lung Cancer","2026-05-11",{"date":404,"type":38},{"date":442,"type":38},"2025-06-04",{"date":410,"type":21},{"name":108,"class":45},18,{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":420,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":46},"100638267","phase-1-phase-12-study-of-eb-nk-301-allogeneic-trop2-car-nk-cells-in-advanced-trop2-expressing-solid-tumors-100638267","NCT07589530","Phase 1\u002F2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","A Phase 1\u002F2, Open-Label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of EB-NK-301 (Allogeneic TROP2-Targeted CAR NK Cells) Following Lymphodepleting Chemotherapy in Adults With Advanced or Metastatic TROP2-Expressing Solid Tumors","SOLID-NK","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of informed consent.\n* Histologically or cytologically confirmed advanced or metastatic solid tumor with documented TROP2 expression (per local testing or central confirmation).\n* Disease progression on, intolerance to, or ineligibility for available standard therapy.\n* At least one measurable lesion per RECIST 1.1.\n* ECOG performance status 0 to 1.\n* Adequate organ function (hematologic, renal, hepatic) within protocol-defined limits.\n* Life expectancy ≥ 12 weeks.\n* Willingness to use effective contraception during study participation and for a protocol-defined period after last infusion (if of childbearing potential).\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) metastases or leptomeningeal disease (unless treated and clinically stable for ≥ 4 weeks).\n* Prior allogeneic hematopoietic stem cell transplant or solid organ transplant.\n* Uncontrolled active infection, including uncontrolled hepatitis B, hepatitis C, or HIV infection.\n* Active autoimmune disease requiring systemic immunosuppression.\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction or stroke within 6 months, uncontrolled arrhythmia).\n* Receipt of another investigational agent within 2 weeks (or 5 half-lives, whichever is longer) prior to lymphodepleting chemotherapy.\n* Prior gene-modified cellular therapy within 3 months prior to enrollment.\n* Systemic corticosteroid therapy \\> 10 mg\u002Fday prednisone equivalent within 7 days prior to lymphodepletion (excluding physiologic replacement).\n* Pregnant or breastfeeding.",{"count":455,"type":21},60,[24,58],"study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy.\n\nThe primary goals are to assess safety and tolerability, identify dose-limiting toxicities (DLTs), and determine a recommended Phase 2 dose (RP2D). Secondary goals include preliminary anti-tumor activity, persistence of infused CAR-NK cells, and exploratory immune biomarkers.",[61,27,459],"TROP2-Expressing Solid Tumors",[461,462,463,464,465,466,467,468,469],"Solid tumors","Immunotherapy","Adoptive cell therapy","Natural killer cells","NK cell therapy","CAR-NK","Dose escalation","Dose expansion","TROP2","2026-05-10",{"date":406,"type":38},{"date":473,"type":38},"2026-03-02",{"date":475,"type":21},"2028-03-17",{"name":477,"class":45},"Beijing Biotech",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":420,"enrollmentInfo":485,"targetDuration":4,"studyType":22,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":46},"100599646","phase-1-a-study-of-skb107-in-advanced-solid-tumors-with-bone-metastases-100599646","NCT07087197","A Study of SKB107 in Advanced Solid Tumors With Bone Metastases","A Multicenter, Open-label Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of SKB107 in Subjects With Advanced Solid Tumors With Bone Metastases","Inclusion Criteria:\n\n1. The age should be between 18 years and 75 years at the time of signing the informed consent form (ICF);\n2. The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1;\n3. The expected survival period should be ≥ 3 months;\n4. Phase Ia: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment;\n5. Phase Ib: Subjects with advanced mCRPC diagnosed by histology or cytology;\n6. Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least one site was confirmed by CT or MRI;\n7. Have adequate organ and bone marrow functions;\n8. For subjects with reproductive capacity, take effective medical contraceptive measures during the study treatment and within 6 months after the last administration;\n9. The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.\n\nExclusion Criteria:\n\n1. The washout period before the first administration of the study drug was insufficient.\n2. Previous received similar radionuclide internal irradiation treatment.\n3. Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases.\n4. Known \"super bone imaging\".\n5. Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.\n6. Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.\n7. Poorly controlled diabetes and hypertension.\n8. The toxicity of previous anti-tumor treatment before the first administration has not recovered to ≤ 1 grade (evaluated based on NCI-CTCAE v5.0) or has not reached the level specified in the inclusion\u002Fexclusion criteria.\n9. Had other malignant tumors within 3 years before the first administration.\n10. Subjects with severe and\u002For uncontrolled concomitant diseases.\n11. Active hepatitis B or active hepatitis C.\n12. Human immunodeficiency virus (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.\n13. Subjects with a history of radionuclide\u002Fradioactive drug allergy, or allergic to any component of the study formulation.\n14. During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.\n15. Subjects participating in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an intervention study.\n16. Any unstable disease or clinical condition, or any condition that may endanger the safety of the subject or affect the subject's compliance, or any other conditions that the investigator deems inappropriate for participation in this study.",{"count":486,"type":21},90,[24],"A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.",[27],"2026-05-05",{"date":492,"type":38},"2026-05-08",{"date":494,"type":38},"2025-08-15",{"date":496,"type":21},"2028-07-01",{"name":498,"class":45},"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":22,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":4},"100628500","phase-1-study-of-qls5308-in-patients-with-advanced-solid-tumors-100628500","NCT07462442","Study of QLS5308 in Patients With Advanced Solid Tumors","A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS5308 Monotherapy in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1.\n* Has adequate organ function.\n* The expected survival period is ≥3 months.\n* Based on the pathological report of the most recent biopsy or other pathological specimens, advanced or metastatic solid tumors confirmed by histology or cytology are not suitable for radical treatments such as surgery and radiotherapy.\n* According to the RECIST v1.1 evaluation criteria, the participants had at least one radiologically measurable lesion.\n\nExclusion Criteria:\n\n* Prior treatment with LIV1-targeting agents, ADCs with topoisomerase 1 inhibitor (TOP1i) payloads, or other TOP1i drugs.\n* There was symptomatic central nervous system (CNS) metastasis, leptomeningeal metastasis or spinal cord compression caused by metastasis before the first use of the investigational product.\n* Active, uncontrolled bacterial, fungal or viral infections.\n* Participants with moderate to large amounts of uncontrolled pleural, pericardial, or peritoneal effusions before the first dose (those who remain stable for at least 2 weeks after drainage may be enrolled).\n* Subjects with a history of a second malignant tumor other than the target indication within 3 years prior to signing the informed consent (excluding cured basal cell skin cancer, superficial bladder cancer, carcinoma in situ of the breast, papillary thyroid carcinoma, etc.).\n* Prior to the first dose of the investigational product, all reversible toxicities from prior anti-tumor therapy (excluding alopecia and pigmentation) have not recovered to ≤ Grade 1 (as assessed by CTCAE v5.0), with the exception that peripheral neuropathy must have not recovered to ≤ Grade 2.\n* Active autoimmune disease that requires systemic treatment or has the potential to recur.",{"count":507,"type":21},192,[24],"The goal of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS5308 monotherapy in participants with Advanced Solid Tumors. This study is divided into two phases: Phase Ia is the dose escalation phase, where dose escalation of QLS5308 conducted and RP2D is explored; In the Phase Ib tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLS5308 with advanced solid tumors.",[27],"2026-03-05",{"date":513,"type":38},"2026-03-10",{"date":515,"type":21},"2026-03-28",{"date":517,"type":21},"2031-08",{"name":519,"class":45},"Qilu Pharmaceutical Co., Ltd.",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":528,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":538},"100601255","phase-1-slv-324-treatment-of-metastatic-solid-tumors-100601255","NCT07108114","SLV-324 Treatment of Metastatic Solid Tumors","A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Men or women (as appropriate for cancer type) of age ≥18 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n3. Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records.\n4. Presence of metastatic disease that has progressed during or following previous treatment.\n5. Presence of radiographically measurable disease.\n6. Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.\n7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.\n8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and\u002For fluorodeoxyglucose (FDG) positron emission tomography (PET)\u002FCT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.\n9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.\n10. Adequate hematological profile.\n11. Adequate coagulation profile.\n12. Adequate hepatic profile.\n13. Adequate renal function.\n14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.\n15. For female subjects of childbearing potential, a negative serum pregnancy test.\n16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.\n17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.\n18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy\u002Faspirations and\u002For radiographic studies), and study restrictions.\n19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.\n4. Significant cardiovascular event or comorbidity.\n5. Significant screening ECG abnormalities.\n6. Pregnancy or breastfeeding.\n7. Major surgery within 4 weeks before the start of study therapy.\n8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.\n9. Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.\n10. Concurrent participation in another therapeutic or imaging clinical trial.\n11. Other conditions likely to interfere with a subject's ability to participate in the study.",{"count":20,"type":21},[24],"This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.",[27],"2026-02-20",{"date":308,"type":38},{"date":534,"type":38},"2025-08-25",{"date":536,"type":21},"2027-08",{"name":44,"class":45},7,{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":46},"100609519","phase-1-phase-iaib-study-of-ckd-512-alone-and-in-combination-with-pembrolizumab-in-subjects-with-advanced-or-metastatic-solid-tumors-100609519","NCT07215637","Phase Ia\u002FIb Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors","A Multicenter, Open-label, Dose-escalation, Phase Ia\u002FIb Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CKD-512 Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumor","Inclusion Criteria:\n\n* Histologically confirmed advanced or metastatic solid tumors.\n* Progressive disease after or intolerance to standard therapy and no other effective therapeutic options available.\n* Measurable disease as defined in Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Suitable venous access for the study-required blood sampling, including PK and PD sampling.\n* Adequate clinical laboratory values and other measures\n\nExclusion Criteria:\n\n* Active disease involvement of the central nervous system.\n* Any serious or life-threatening medical condition unrelated to cancer, psychiatric illness, drug or alcohol abuse, that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Systemic anticancer treatment within the protocol-specified period prior to the first dose.\n* History of any immune-related toxicity that lead to permanent discontinuation of prior anticancer therapy\n* Radiation therapy on a limited area is allowed until 4 weeks prior to the first dose of study drug, provided that the radiated lesion is clinically stable.\n* Prior treatment with investigational agents ≤21 days before the first dose of study drug(s).",{"count":455,"type":21},[24],"The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors who have failed all standard available therapy.",[61,27],[551,552,553,61,27],"A2aR","adenosine A2A receptor","CKD-512","2026-01-29",{"date":556,"type":38},"2026-02-02",{"date":558,"type":38},"2025-10-16",{"date":560,"type":21},"2027-09",{"name":562,"class":45},"Chong Kun Dang Pharmaceutical",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":46},"100618595","phase-2-image-guided-125i-seed-implantation-plus-standard-systemic-therapy-for-patients-with-multiple-metastatic-lesions-100618595","NCT07333664","Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions","Standard-of-Care Systemic Therapy With or Without Image-Guided 125I Seed Implantation in Patients With Multiple (6-10) Metastatic Lesions: A Randomized Phase 2 Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or cytologically confirmed malignant solid tumor with metastatic disease.\n* Presence of more than five and up to ten (6-10) extracranial metastatic lesions, identified on CT or PET\u002FCT imaging and assessable by RECIST version 1.1 (and\u002For PERCIST when PET imaging is used).\n* At least one metastatic lesion considered suitable for image-guided iodine-125 (125I) seed implantation according to institutional assessment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate organ function to undergo interventional procedures and systemic therapy, as determined by institutional standards.\n* Ability to understand and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Diffuse or unstable central nervous system involvement, including leptomeningeal disease or uncontrolled\u002Fsymptomatic brain metastases requiring immediate local intervention.\n* Medical conditions that preclude safe interventional procedures, including uncontrolled infection, severe cardiopulmonary dysfunction, or other serious systemic illness, as judged by the investigator.\n* Contraindications to percutaneous implantation, such as uncorrectable coagulation disorders, high bleeding risk, lack of a safe needle path, or unacceptable risk to critical organs.\n* Pregnancy or breastfeeding.\n* Inability to provide informed consent or comply with study procedures, due to severe psychiatric illness, cognitive impairment, or other limiting conditions.\n* Any other condition that, in the investigator's judgment, would make the patient unsuitable for study participation or compromise patient safety or study integrity.",{"count":571,"type":21},120,[58],"Patients with more than five and up to ten metastatic lesions often have limited tolerance for surgery, radiotherapy, or thermal ablation because of cumulative treatment burden or expected toxicity. In this setting, systemic therapy alone frequently remains the primary treatment option.\n\nThis prospective, open-label, randomized phase 2 study evaluates whether image-guided iodine-125 (125I) seed implantation, when added to standard-of-care systemic therapy, can improve disease control compared with standard systemic therapy alone in patients with multiple metastatic lesions. Clinical outcomes including progression-free survival, overall survival, safety, and quality of life will be prospectively assessed.",[27],[576,577,578],"Multiple Metastases","lodine-125 Seed Brachytherapy","Image-Guided Therapy","2026-01-02",{"date":581,"type":38},"2026-01-12",{"date":583,"type":21},"2026-01",{"date":585,"type":21},"2028-01-01",{"name":587,"class":588},"Li Min","OTHER",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":4},"100616549","phase-1-rare-tumor-focused-platform-study-of-innovative-therapies-and-technologies-platform2-100616549","NCT07307053","Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","An Open-Label, Single-Arm, Phase I\u002FII Platform Trial of Innovative Therapies and Technologies Primarily in Rare Tumors in China (PLATFORM2) in Patients With Advanced Solid Tumors","Inclusion Criteria\n\n1. Subjects must meet all of the following inclusion criteria:\n2. Male or female subjects aged ≥16 years at the time of signing the informed consent form.\n3. Histologically or cytologically confirmed malignancy.\n4. ECOG performance status of 0-2 and an expected survival of more than 12 weeks.\n5. Presence of measurable or evaluable disease for efficacy assessment, as determined by the investigator according to the individualized criteria defined in each sub-protocol.\n6. Provision of fresh tumor biopsy tissue is recommended, obtained within 12 weeks prior to the first administration of study treatment, consisting of three core needle biopsy specimens. The biopsy tissue must not have been exposed to any antitumor therapy, systemic anti-infective treatment, or vaccination after collection. Peripheral blood samples are also recommended for molecular profiling and enrollment screening.\n7. Provision of archival formalin-fixed paraffin-embedded (FFPE) tumor tissue from the primary lesion or a metastatic lesion (excluding bone metastases and lesions previously treated with radiotherapy) obtained within the past 2 years is recommended. The required material includes 15-20 unstained slides (4-6 μm thickness), of which 5 slides should be adhesive-coated and baked. If the above requirements cannot be met, enrollment eligibility may be determined at the investigator's discretion.\n8. If pleural or peritoneal effusion is present, samples must be collected for pathological cytological examination, and provision of at least 50 mL of effusion fluid is recommended, if available.\n9. If a primary tumor biopsy specimen has been provided, and a metastatic lesion is amenable to biopsy (as judged by the investigator), tissue from the metastatic lesion should be collected for pathological examination, and fresh tissue specimens are recommended.\n10. Upon disease progression, if conditions permit (as judged by the investigator), collection of fresh tumor tissue from the same biopsy site at enrollment and\u002For from previously sampled metastatic lesions is recommended.\n11. Toxicities from prior therapies must have resolved to ≤ Grade 1 or returned to baseline, according to NCI-CTCAE version 5.0, except for alopecia.\n12. A negative pregnancy test is required for women of childbearing potential. Women not of childbearing potential are defined as those who are postmenopausal for at least 1 year, or who have undergone surgical sterilization or hysterectomy.\n13. All enrolled subjects, regardless of sex, must agree to use effective contraception throughout the treatment period and for 8 weeks after the last dose of study treatment.\n14. Subjects must voluntarily participate, provide written informed consent, comply with the study treatment and visit schedule, and be able to cooperate with safety and efficacy assessments.\n\nExclusion Criteria\n\nSubjects meeting any of the following exclusion criteria will not be eligible for participation in this study:\n\n1. Prior treatment with any antitumor novel drug or technology of the same class as that investigated in the relevant sub-protocol of this study.\n2. Known hypersensitivity or allergy to any active component or excipient of the investigational antitumor novel drug or technology.\n3. Presence of any type of interstitial lung disease or a history of radiation pneumonitis.\n4. Failure to meet the inclusion or exclusion criteria specified in the applicable sub-protocol.\n5. Major surgery performed within 4 weeks prior to the first administration of study treatment, or surgical wounds that have not fully healed.\n6. History of hypersensitivity reactions to drugs whose chemical structures are similar to the active or inactive components of the investigational antitumor novel drug or technology, or to agents of the same class.\n7. Active infection requiring systemic therapy (e.g., antibiotics), or the presence of any of the following conditions:\n\n   * Positive human immunodeficiency virus (HIV) test or a known history of acquired immunodeficiency syndrome (AIDS);\n   * Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, defined as HBsAg positivity with HBV DNA levels above the upper limit of normal (ULN), or HCV antibody positivity;\n   * Active tuberculosis, defined as a history of exposure or a positive tuberculosis test accompanied by clinical symptoms and\u002For radiographic findings.\n8. Evidence of severe or uncontrolled systemic disease, as determined by the investigator, including but not limited to severe psychiatric or neurological disorders (such as epilepsy or dementia), unstable or uncompensated respiratory, cardiovascular, hepatic, or renal disease, or uncontrolled hypertension (defined as blood pressure remaining at or above CTCAE Grade 3 despite medical treatment).\n9. Myocardial infarction, coronary artery bypass grafting, peripheral artery bypass grafting, or cerebrovascular accident occurring within 3 months prior to enrollment.\n10. History of any organ transplantation, including allogeneic hematopoietic stem cell transplantation, except for transplants not requiring immunosuppressive therapy (e.g., corneal transplantation or hair transplantation).\n11. Presence of cardiovascular disease or conditions including any of the following:\n\n    * Congestive heart failure requiring treatment, or New York Heart Association (NYHA) Class III or IV heart failure;\n    * Ventricular arrhythmias requiring antiarrhythmic therapy, or uncontrolled or unstable arrhythmias;\n    * Severe conduction abnormalities, such as second- or third-degree atrioventricular block;\n    * Angina pectoris requiring treatment;\n    * Prolonged QT interval on 12-lead electrocardiogram, defined as QTc ≥450 ms for males or ≥470 ms for females;\n    * History of congenital long QT syndrome, congenital short QT syndrome, torsades de pointes, or pre-excitation syndrome;\n    * Left ventricular ejection fraction (LVEF) \\\u003C50%, as determined by echocardiography or MUGA scan;\n    * Myocardial infarction diagnosed within the past 6 months.\n12. Inadequate bone marrow reserve or organ function, as evidenced by any of the following laboratory findings:\n\n    * Absolute neutrophil count \\\u003C1.0 × 10⁹\u002FL;\n    * Platelet count \\\u003C80 × 10⁹\u002FL (patients dependent on platelet transfusion are excluded);\n    * Hemoglobin \\\u003C90 g\u002FL;\n    * In the absence of liver metastases, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2.5 × ULN; in the presence of liver metastases, ALT or AST \\>5 × ULN (as determined by the investigator per sub-protocol);\n    * In the absence of liver metastases, total bilirubin \\>1.5 × ULN; in patients with Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases, total bilirubin \\>3 × ULN (as determined by the investigator per sub-protocol);\n    * Serum creatinine \\>1.5 × ULN with concomitant creatinine clearance \\\u003C50 mL\u002Fmin (measured or calculated using the Cockcroft-Gault formula); creatinine clearance assessment is required only when serum creatinine exceeds 1.5 × ULN;\n    * Coagulation abnormalities, defined as INR, PT, or APTT \\>1.5 × ULN in patients not receiving anticoagulant therapy; eligibility of patients receiving anticoagulants will be determined by the investigator;\n    * Elevated creatine kinase (CK) or CK-MB above the normal range (as determined by the investigator per sub-protocol).\n13. Pregnant or breastfeeding women.\n14. Any other condition that, in the opinion of the investigator, may pose a potential risk or render the subject unsuitable for participation in this study.",{"count":222,"type":21},[24,58],"The goal of this Phase I\u002FII observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols.\n\nKey questions it aims to answer:\n\nAssess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.",[600,61,27],"Rare Malignant Neoplasm",[602,603,604,462,605,606,607,608,609],"Rare Tumors","Platform Trial","Precision Medicine","Targeted Therapy","Cell and gene therapy","Tumor vaccine","Protein drug","Oncolytic virus","2025-12-13",{"date":612,"type":38},"2025-12-29",{"date":614,"type":21},"2026-01-01",{"date":616,"type":21},"2031-01-31",{"name":618,"class":588},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":641},"100605177","phase-1-a-study-of-ds3610a-in-participants-with-advanced-solid-tumor-100605177","NCT07159126","A Study of DS3610a in Participants With Advanced Solid Tumor","A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor","Key Inclusion Criteria:\n\n* Sign and date the main ICF, prior to the start of any trial-specific procedures.\n* Adults ≥18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is \\>18 years old).\n* Relapsed from, refractory to, or intolerant to appropriate therapies (eg, SoC) to provide clinical benefit for their condition as assessed by their physician and\u002For investigator.\n* Is willing and able to provide an adequate pretreatment tissue sample prior to trial intervention or archival tumor tissue sample.\n* Has measurable disease based on local CT\u002FMRI imaging as assessed by the investigator per RECIST v1.1; radiographic tumor assessment must be performed within 28 days prior to initiation of trial intervention.\n\nKey Exclusion Criteria:\n\n\\*Inadequate washout period before initiation of trial intervention, defined as: Major surgery: ≤4 weeks (or ≤2 weeks for low-invasive cases) Curative radiation therapy: ≤4 weeks Chemotherapy, Ab-based anticancer therapy, immunotherapy: ≤4 weeks Small molecules (eg, tyrosine kinase inhibitors): ≤2 weeks or 5 half-lives, whichever is longer Nitrosoureas: ≤6 weeks\n\n* Has known symptomatic CNS metastases, leptomeningeal disease, or cord compression. Note: Asymptomatic or adequately treated CNS metastases are not exclusionary provided that, in the opinion of the investigator, the participant is neurologically stable. MRI\u002FCT of the brain is required for all participants during SCR Period\n* Uncontrolled or clinically significant cardiovascular disease, including the following:\n\n  1. Myocardial infarction within 6 months prior to SCR.\n  2. Uncontrolled angina pectoris within 6 months prior to SCR.\n  3. New York Heart Association (NYHA) Class III or IV CHF.\n  4. LVEF ≤50%.\n  5. QTcF interval \\>470 ms.\n* Any of the following within the past 6 months prior to enrollment: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic events.\n* Clinically severe pulmonary compromise (ie, requiring any supplemental oxygen) resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the trial enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.) and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy.",{"count":20,"type":21},[24],"This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.",[99,27],[631],"DS3610a","2025-12-03",{"date":634,"type":38},"2025-12-10",{"date":636,"type":38},"2025-10-09",{"date":638,"type":21},"2031-02-01",{"name":640,"class":45},"Daiichi Sankyo",2,{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":652,"briefSummary":653,"conditions":654,"keywords":655,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":666},"100594626","phase-1-a-study-of-eras-4001-in-patients-with-advanced-or-metastatic-solid-tumors-100594626","NCT07021898","A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.","A Phase 1 First-in-Human Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-4001 Monotherapy and in Combination in Patients With Advanced Solid Tumors","BOREALIS-1","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing and able to give written informed consent\n* Pathological documentation of tumor type and mutation prior to the first dose of study drug(s)\n* There is no available standard systemic therapy available for the patient's tumor histology and\u002For molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy\n* Able to swallow oral medication\n* Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Adequate cardiovascular, hematological, liver, and renal function\n* Willing to comply with all protocol-required visits, assessments, and procedures\n\nExclusion Criteria:\n\n* Previous treatment with a RAS inhibitor\n* Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-4001\n* Received prior palliative radiation within 14 days of Cycle 1, Day 1\n* Have primary central nervous system (CNS) tumors\n* Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption\n* Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs\n* Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial",{"count":651,"type":21},200,[24],"The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.",[27],[227,228,656,230,231,232,657,234,235,658,237],"Solid malignancies","Keytruda","Metastatic solid tumor","2025-12-02",{"date":632,"type":38},{"date":662,"type":38},"2025-08-06",{"date":664,"type":21},"2028-12",{"name":248,"class":45},5,{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":4,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":674,"targetDuration":4,"studyType":22,"phases":675,"briefSummary":676,"conditions":677,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":684,"locationsCount":4},"100613899","phase-1-study-of-qlc5513-in-combination-with-epalolimab-tovolimab-ql1706--platinum-in-patients-with-advanced-or-metastatic-malignant-solid-tumors-100613899","NCT07272590","Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors","An Open, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors","Inclusion Criteria:\n\n1. Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1.\n2. Has adequate organ function.\n3. The expected survival period is ≥3 months.\n4. Based on the pathological report of the most recent biopsy or other pathological specimens, advanced or metastatic solid tumors confirmed by histology or cytology are not suitable for radical treatments such as surgery and radiotherapy.\n5. According to the RECIST v1.1 evaluation criteria, the participants had at least one radiologically measurable lesion.\n\nExclusion Criteria:\n\n1. Prior treatment with TROP2-targeting agents, ADCs with topoisomerase 1 inhibitor (TOP1i) payloads, or other TOP1i drugs.\n2. There was symptomatic central nervous system (CNS) metastasis, leptomeningeal metastasis or spinal cord compression caused by metastasis before the first use of the investigational product.\n3. Active, uncontrolled bacterial, fungal or viral infections.\n4. Radiotherapy with more than 25% of the bone marrow exposed within 4 weeks prior to the first use of the investigational drug; Local radiotherapy (excluding brain radiotherapy) was performed within two weeks before the first use of the investigational drug.\n5. Subjects with a history of a second malignant tumor other than the target indication within 5 years prior to signing the informed consent (excluding cured basal cell skin cancer, superficial bladder cancer, carcinoma in situ of the breast, papillary thyroid carcinoma, etc.).\n6. Prior to the first dose of the investigational product, all reversible toxicities from prior anti-tumor therapy (excluding alopecia and pigmentation) have not recovered to ≤ Grade 1 (as assessed by CTCAE v5.0), with the exception that peripheral neuropathy must have not recovered to ≤ Grade 2. History of irAEs from prior immune checkpoint inhibitor treatment that required permanent discontinuation of the immune checkpoint inhibitor.\n7. Active autoimmune disease that has required systemic treatment in the past 2 years.",{"count":282,"type":21},[24,58],"The goal of this Phase Ib\u002FII interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant solid tumors. This study is divided into two phases: Phase Ib is the combined dose escalation phase, where dose escalation of QLC5513 combined with QL1706± platinum is conducted and RP2D is explored; In the Phase II tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLC5513 combined with QL1706± platinum-based treatment in patients with advanced or metastatic malignant solid tumors.",[27],"2025-11-26",{"date":680,"type":38},"2025-12-09",{"date":682,"type":21},"2025-12-30",{"date":517,"type":21},{"name":519,"class":45},{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":690,"acronym":4,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":692,"targetDuration":4,"studyType":22,"phases":694,"briefSummary":695,"conditions":696,"keywords":697,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":701,"startDateStruct":703,"completionDateStruct":705,"leadSponsor":707,"locationsCount":46},"100612154","phase-1-a-study-of-bpr-6023021-in-advanced-solid-tumors-with-bone-metastases-100612154","NCT07249892","A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases","A Multicenter, Open-label Phase I\u002FII Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Dosimetry and Efficacy of BPR-6023021 in Subjects With Advanced Solid Tumors With Bone Metastases.","Inclusion Criteria\n\n1. The age should be up to 18 years at the time of signing the informed consent form (ICF);\n2. The Eastern Cooperative Oncology Group (ECOG) performance status score should be ≤ 1;\n3. The expected survival period should be ≥ 3 months\n4. Phase I and phase II: Subjects with advanced solid tumor bone metastases diagnosed by histology or cytology; and the subjects have failed standard treatment, or have no standard treatment, or are intolerant or not applicable to standard treatment\n5. Before the first administration, a 99mTc-MDP bone scan diagnosed multiple bone metastases, and at least two site was confirmed by CT or MRI;\n6. Have adequate organ and bone marrow functions;\n7. For subjects with reproductive capacity, take effective medical contraceptive measures during the study treatment and within 6 months after the last administration;\n8. The subjects voluntarily join this study, sign the informed consent form, and can comply with the visit and related procedures stipulated in the protocol.\n\nExclusion Criteria\n\n1. The washout period before the first administration of the study drug was insufficient.\n2. Previous received similar radionuclide internal irradiation treatment.\n3. Previous received or planned to receive during the study period semi-body external radiotherapy targeting bone metastases.\n4. Known \"super bone imaging\".\n5. Known spinal cord compression, or clinical imaging manifestations suggesting impending spinal cord compression.\n6. Any cardiovascular or cerebrovascular diseases or cardiovascular risk factors that may affect the treatment of the study drug.\n7. Poorly controlled diabetes and hypertension.\n8. The toxicity of previous anti-tumor treatment before the first administration has not recovered to ≤ 1 grade (evaluated based on NCI-CTCAE v5.0) or has not reached the level specified in the inclusion\u002Fexclusion criteria.\n9. Had other malignant tumors within 5 years before the first administration.\n10. Subjects with severe and\u002For uncontrolled concomitant diseases.\n11. Active hepatitis B or active hepatitis C.\n12. Human immunodeficiency virus (HIV) test positive or having a history of acquired immune deficiency syndrome (AIDS); known active syphilis infection.\n13. During the screening process before the first administration, the condition deteriorated rapidly, such as significant changes in the investigator's assessment of physical condition, etc.",{"count":693,"type":21},195,[24,58],"A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases",[27],[698,61,699],"BPR-6023021","Bone Metastases","2025-11-18",{"date":702,"type":38},"2025-11-25",{"date":704,"type":21},"2025-11-19",{"date":706,"type":21},"2027-09-06",{"name":708,"class":45},"Chengdu Syncor Pharmaceutical Co., Ltd.",{"id":710,"slug":711,"hasResults":12,"nctId":712,"briefTitle":713,"officialTitle":714,"acronym":4,"eligibilityCriteria":715,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":716,"enrollmentInfo":717,"targetDuration":4,"studyType":22,"phases":719,"briefSummary":720,"conditions":721,"keywords":724,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":700,"lastUpdatePostDateStruct":738,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":743,"locationsCount":744},"100369766","phase-1-a-study-of-repotrectinib-in-pediatric-and-young-adult-subjects-harboring-alk-ros1-or-ntrk1-3-alterations-100369766","NCT04094610","A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","A Phase 1\u002F2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations","Key Inclusion Criteria:\n\n1. Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.\n2. Phase 1: Age \\\u003C12 years; Phase 2: Age 12- 25 years\n3. Prior cytotoxic chemotherapy is allowed.\n4. Prior immunotherapy is allowed.\n5. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.\n6. All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment.\n7. Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment.\n8. Subjects must have a Lansky (\\\u003C 16 years) or Karnofsky (≥ 16 years) score of at least 50.\n9. Life expectancy greater than or equal to 12 weeks, in the investigator's opinion.\n10. Adequate hematologic, renal and hepatic function.\n\nPhase 2 Inclusion Criteria:\n\n1. Cohort Specific Inclusion Criteria:\n\n   * Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI naïve;\n   * Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS tumors), that are TRK TKI pre-treated;\n   * Cohort 3: subjects with advanced solid tumors with ROS1 gene fusions or other ROS1 aberrations (including amplifications and point mutations) with measurable disease.\n2. Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment.\n\nKey Exclusion Criteria (Phase 1 and Phase 2):\n\n1. Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.\n2. Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.\n3. Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).\n4. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.\n5. Any of the following cardiac criteria:\n\n   * Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \\> 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value\n   * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \\> 250 msec)\n   * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval\n6. Peripheral neuropathy of CTCAE ≥grade 2.\n7. Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.\n8. Any potential allergies to repotrectinib and\u002For its excipients.","25 Years",{"count":718,"type":21},75,[24,58],"Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D).\n\nPhase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.",[327,27,722,723],"Lymphoma","Primary CNS Tumors",[329,330,725,726,727,728,729,730,731,732,733,734,735,736,737],"NTRK1-3","Primary CNS tumor","anaplastic large cell lymphoma","metastatic solid tumor","advanced solid tumor","sarcoma","infantile fibrosarcoma","glioblastoma","soft tissue schwannoma","solitary fibrous tumor","glioma","inflammatory myofibroblastic tumor","pediatric",{"date":704,"type":38},{"date":740,"type":38},"2020-03-12",{"date":742,"type":21},"2027-09-30",{"name":378,"class":45},68,{"id":746,"slug":747,"hasResults":12,"nctId":748,"briefTitle":749,"officialTitle":749,"acronym":4,"eligibilityCriteria":750,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":751,"targetDuration":752,"studyType":753,"phases":4,"briefSummary":754,"conditions":755,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":756,"lastUpdatePostDateStruct":757,"startDateStruct":759,"completionDateStruct":761,"leadSponsor":763,"locationsCount":46},"100596539","a-multicenter-prospective-non-interventional-real-world-study-of-iparomlimab-and-tuvonralimab-injection-ql1706-in-the-treatment-of-locally-advanced-or-metastatic-solid-tumors-100596539","NCT07046780","A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* 1\\) Histologically or cytologically confirmed locally advanced or metastatic solid tumors with disease progression (radiographic or clinical) after ≥1 line of prior standard therapy, unsuitable for\u002Fintolerant to standard therapy. Includes but not limited to: Gastrointestinal tumors (colorectal cancer, hepatocellular carcinoma, esophageal cancer, biliary tract cancer, pancreatic cancer, gastric cancer), Breast cancer, Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Soft tissue sarcoma;\n* 2\\) ECOG performance status 0-2;\n* 3\\) ≥1 measurable lesion per RECIST v1.1 ;\n* 4\\) Adequate organ function meeting ALL criteria below:\n\n  1. Hematology (without transfusion\u002FG-CSF support within 7 days):\n\n     Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL Platelets ≥100×10⁹\u002FL Hemoglobin ≥90 g\u002FL\n  2. Biochemistry :\n\n     Total bilirubin (TBIL) ≤2×ULN ALT\u002FAST ≤2.5×ULN (≤5×ULN if liver metastases present) Serum creatinine (Cr) ≤1.5×ULN Albumin ≥28 g\u002FL\n  3. Urinalysis :\n\n     Urine protein \\\u003C2+ (dipstick) If protein ≥2+, 24h urinary protein ≤1.0 g\n  4. Coagulation (without anticoagulants):\n\nPT\u002FAPTT\u002FINR ≤1.5×ULN\n\n* 5\\) Life expectancy ≥12 weeks;\n* 6\\) Contraception : Females of childbearing potential or males with partners of childbearing potential must use effective contraception during treatment and for 6 months post-treatment;\n* 7\\) Signed informed consent and protocol compliance.\n\nExclusion Criteria:\n\n* 1\\) Tumor-Related Conditions\n\n  1. Known CNS metastases (except those radiologically stable ≥4 weeks after radiotherapy);\n  2. Other malignancies within past 5 years, excluding:\n\n     Cured basal\u002Fsquamous cell skin cancer Localized low-risk prostate cancer Cervical\u002Fbreast carcinoma in situ\n  3. Severe bone lesions from metastatic disease, including:\n\n     Uncontrolled bone pain Pathologic fractures at critical sites (within 6 months) or impending spinal cord compression;\n  4. Uncontrolled effusions requiring recurrent drainage (pleural\u002Fpericardial\u002Fascites), per investigator assessment.\n* 2\\) Prior Anti-tumor Therapy\n\n  1. Prior systemic therapy with CTLA-4 inhibitors or other ICIs;\n  2. Any anti-tumor treatment within 4 weeks before first dose, including:\n\n     Surgery\u002Fchemotherapy\u002Fpalliative radiotherapy to non-target lesions\u002Fhormonal\u002Ftargeted\u002Fbiologic\u002Fimmunotherapy;\n  3. Treatment-related toxicities not recovered to CTCAE grade ≤1 (exceptions: alopecia\u002Fplatinum-induced neuropathy ≤ grade 2).\n* 3\\) Comorbidities \\& History\n\n  1. Arterial thromboembolism within 6 months (MI\u002Funstable angina\u002Fstroke\u002FTIA);\n  2. Symptomatic heart failure (NYHA class III-IV), unstable angina, or uncontrolled arrhythmia;\n  3. Severe pulmonary disease : ILD\u002FCOPD\u002Fsymptomatic bronchospasm;\n  4. Active uncontrolled infection (≥CTCAE grade 2), including:\n\n     HIV Active HBV (DNA ≥500 IU\u002FmL) HCV (Ab+ with detectable RNA) HBV\u002FHCV co-infection;\n  5. History of neurologic\u002Fpsychiatric disorders;\n  6. Recent or current substance abuse;\n  7. Prior allogeneic organ\u002Fhematopoietic stem cell transplantation.\n* 4\\) Hypersensitivity to study drug or its excipients.\n* 5\\) Active autoimmune disease requiring treatment or history within 2 years. Exceptions: Vitiligo\u002Falopecia\u002Fpsoriasis not needing systemic therapy Hypothyroidism managed only with hormone replacement Type 1 diabetes controlled solely with insulin.\n* 6\\) Pregnant\u002Flactating women;\n* 7\\) Any uncontrolled systemic disease increasing study risk (per investigator);\n* 8\\) Other unsuitable conditions determined by investigator.",{"count":486,"type":21},"2 Years","OBSERVATIONAL","This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab Injection (QL1706). The primary objectives are to evaluate the safety and effectiveness of Iparomlimab and Tuvonralimab Injection (QL1706) in treating locally advanced or metastatic solid tumors.",[95,27,96],"2025-06-23",{"date":758,"type":38},"2025-07-02",{"date":760,"type":21},"2025-07-30",{"date":762,"type":21},"2027-12-30",{"name":764,"class":588},"PENG YUAN"]